Showing posts with label Recent Lawsuits in Mesothelioma. Show all posts
Showing posts with label Recent Lawsuits in Mesothelioma. Show all posts

Thursday, 3 December 2009

Mesothelioma drug listed on PBS

UFFERERS of the asbestos-linked disease mesothelioma will have access to cheap treatment from today, after a long campaign to secure federal government subsidy paid off.

The government says the chemotherapy agent Alimta - the only treatment available specifically for the killer cancer of the lung or stomach lining - will be listed on the Pharmaceutical Benefits Scheme (PBS) from today.

Health Minister Nicola Roxon said the listing of Alimta was an important announcement that followed the "tireless campaigning" of Bernie Banton, who died, aged 61, in November from the disease.

"Bernie was a great Australian hero and it is due to his efforts that many people will understand the significance of this decision," she said.

About 600 Australians are diagnosed annually with mesothelioma, but the long lag time between exposure to asbestos and the onset of symptoms means its prevalence is tipped to rise in the future.

Medical studies have estimated 18,000 people will have become victims of the disease by 2020.

Alimta, which can increase survival time and improve a sufferer's quality of life, has been out of reach for many patients at $20,000 or more for six treatments.

From today, sufferers will pay a maximum of $31.30 for each prescription. Eligible concession-patients will pay $5 for each prescription.

The subsidy will cost the government about $26 million annually and is expected to benefit about 300 people a year.

The listing of the drug became an election issue after Mr Banton criticised then health minister Tony Abbott for failing to personally receive a 17,000-signature petition brought to his Sydney electoral office in October.

Mr Abbott was forced into an embarrassing apology after questioning whether the dying campaigner's motives for speaking out were "pure of heart".

A week later, a government-appointed board recommended the drug be added to the PBS after three times rejecting its listing since 2004.

Mr Abbott bypassed the normal process of cabinet approval by immediately announcing the drug's listing.

Until now, only about half of Australians suffering mesothelioma were getting easy access to the palliative care drug through state government subsidy and workplace compensation schemes.

Alfacell Deals U.S. Rights for Onconase to Strativa

Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million.

Just $5 million will change hands up front, but both Alfacell and Strativa stand to gain much more if their gamble in choosing each other as partners pays off. Specifically, Alfacell could get $30 million for FDA approval of Onconase in unresectable malignant mesothelioma (UMM) and up to $190 million for milestones tied to Onconase sales as well as development and commercialization of the drug in additional indications. Alfacell also would receive double-digit royalties and retains a co-promotion option.

For Alfacell, the gamble lies in choosing Strativa, the recently-launched specialty pharmaceutical division of Par Pharmaceutical Cos. Inc. So far, Strativa markets just one product: Megace ES for anorexia, cachexia and unexplained weight loss in HIV patients. Although the company has deals in place for three additional late-stage products, all three are for HIV or cancer supportive care, and Onconase would be Strativa's first true oncology therapeutic.

Lawrence Kenyon, executive vice president and chief financial officer for Alfacell, told BioWorld Today that Onconase has been the subject of "bids from multiple companies for a number of years." Strativa was selected because it had the hunger of a start-up looking to build an oncology business focused on niche products, combined with the resources and infrastructure of Par Pharmaceuticals, he said.

For Strativa, the gamble lies in Onconase's somewhat checkered development history. The drug, a natural ribonuclease isolated from frog eggs, failed a Phase III trial in pancreatic cancer and its first Phase III trial in UMM.

In the pancreatic cancer trial, a preliminary analysis showed that Onconase plus tamoxifen failed to improve survival compared to 5-fluorouracil. Kenyon said part of the problem was an inability to recruit sufficiently healthy patients into the trial, and the pancreatic cancer program subsequently was discontinued. (See BioWorld Today, July 16, 1998.)

The first Phase III UMM trial compared Onconase as a monotherapy to doxorubicin. Again, there was no survival difference in the overall population, but Kenyon said a retrospective analysis showed that the sickest patients had been disproportionately weighted to the Onconase group. Backing them out of the analysis resulted in a two-month survival difference.

Onconase is now being studied in a Phase IIIb trial designed to confirm the positive data seen in the Phase III subset analysis. The trial, which was designed in coordination with the FDA, compares Onconase plus doxorubicin to doxorubicin alone in the less-severe groups of UMM patients. Enrollment of 428 patients is complete, and Kenyon said the company is "very close" to obtaining the number of clinical events needed to analyze the data.

Under the deal with Strativa, Alfacell will continue to fund development, manufacturing and regulatory work with Onconase, including the ongoing Phase IIIb trial. Strativa will fund U.S. commercialization.

Previous deals with US Pharmacia affiliate USP Pharma Spolka Z.O.O. and Genesis Pharma SA cover Onconase commercialization in Eastern Europe and certain Southeast European countries, respectively.

As of Oct. 31, Alfacell reported $5.4 million in cash and equivalents, most of which was earmarked to support the Onconase trial and new drug application filing. Once the filing is submitted, Alfacell intends to work with Strativa on additional indications for Onconase, including the possibility of moving a non-small-cell lung cancer program into Phase II.

Kenyon said the money from Strativa also will allow Alfacell to "ramp up" its preclinical work on AC 03-636 for glioma and antiviral indications, AC CJ-001 for glioma, and AC CJ-002 for non-Hodgkin's lymphoma.
Shares of Somerset, N.J.-based Alfacell (NASDAQ:ACEL) rose 25 cents, or 14.3 percent, to close at $2 on Tuesday. Meanwhile, shares of Woodcliff Lake, N.J.-based Par Pharmaceuticals (NYSE:PRX) rose 52 cents to close at $21.49.

Vermont Mesothelioma Lawyer Shepard helping Mesothelioma Victims in Rhode Island, Boston, New York, New Hampshire

The Mesothelioma Lawyer expresses his concern over the student’s health risks as asbestos that was used in these old school buildings as the primary insulation and fireproofing construction material is now projecting from the school building sites due to poor maintenance. It is contaminating the schools environment posing students, teachers and the staff to mesothelioma cancer and asbestos related respiratory diseases.

The school going students and the staff working in these schools are exposed to the risk of asbestos related respirator diseases thus laying the foundation for mesothelioma. This fact is also reviled by the Mesothelioma and Asbestos Awareness Centers report. The school buildings in New York have now grown old and need maintenance. Due to lack of maintenance in the old building the asbestos which had been used in construction is now exposed. It is polluting the environment endangering the lives of students, teachers and staff exposing them to the risk of contracting asbestos related respiratory diseases and mesothelioma cancer.

During an emergency inspection in NY schools which was carried as a NY City School was blamed for an incident of asbestos exposure. It was reveled during the inspection that 80% of the building built prior to 1980 used asbestos as insulation and fire proof material during the construction phase. Now due to the poor maintenance the risk of exposure of asbestos has increased manifolds posing risk of health to all the occupants of the school buildings. The report by the Mesothelioma and Asbestos Awareness Centers Report also state that in 2004 one Brooklyn School was forced to open late as they had to ensure the safety of the school building, staff and the students.

Even a small amount of asbestos exposure contaminates the environment, increases the possibility of inhalation of asbestos particles thus marking a start of respiratory disorders leading to mesothelioma cancer.

Mesothelioma lawyer Shepard studies all such cases, takes the path of law to bring relief to the injured who had not known about the risks of being exposed to asbestos. At present Shepard Law Firm is assisting Mesothelioma victims in:

* Boston
* New Hampshire
* Vermont
* Rhode Island

However, due to large network Shepard Law firm enjoys, cases from other areas such as Dallas, New York, Houston and other areas where school buildings are getting old and may be of concern resulting in asbestos exposure can contact: The Shepard Law Firm at http://www.shepardlawfirm.com

To learn more about Mesothelioma / Asbestos Risks visit Mesothelioma Cancer Resource
for free informaation

Razed home's owner takes step to sue city

$1M NOTICE OF CLAIM: Columbia Street residence, called 'the cat house,' was torn down after fire Nov. 12

The man who owns a home on Columbia Street that was referred to as "the cat house" by neighbors has filed a notice of claim for $1 million against the city of Watertown for razing its remains after a fire last year.

A notice of claim is a precursor to filing a lawsuit against a municipality.

Oliver J. Wisner is seeking compensation for the "arbitrary, capricious and malicious charging and billing for outrageous unnecessary work on the cleanup of ashes and debris" the claim states.

The Watertown lawyer owns the property at 1205-07 Columbia St., which burned down Nov. 12, forcing neighbors to evacuate their homes during the early morning hours. The heat from the blaze damaged nearby homes, one of which is still uninhabitable.

The city requested that Mr. Wisner remove the remaining debris from the duplex immediately following the blaze. In late December, the city hired Independent Commercial Contractors Inc., Lorraine, for $28,600 to clean the site and remove asbestos. Mr. Wisner was then billed for the job.

Mr. Wisner bought the home June 21, despite the previous owner not allowing him to completely inspect it beforehand, the notice states.

Once the purchase was complete, Mr. Wisner hired cleaners to clear debris from the home.

"The cleaners discovered more than 10 bodies of long-dead cats in the building," the notice states. "The odor from the house and the Dumpsters brought numerous complaints from neighbors."

In June, the city Code Enforcement Office found that an upstairs bathtub in 1205 Columbia St. was filled with cat feces, and cat skeletons were found throughout the apartment.The property was condemned and the tenant, Michael J. Sias, was removed.

Mr. Sias, 58, now of 536 Emerson St., Apt. 103, is facing an animal-cruelty charge on allegations that between June 25 and July 3 he deprived seven cats of necessary sustenance in his former home, "permitting unjustifiable physical pain, suffering and death," according to a city police document. He was charged Tuesday and faces prosecution in City Court.

Some live cats were taken from the home by the SPCA, others were euthanized and six frozen bodies that were found in an operating freezer were sent to Cornell University, Ithaca, for a forensics examination.

Mr. Wisner claims that "it was a matter of public knowledge that persons in the city of Watertown, New York, had called for the burning of the duplex." Throughout the notice, he maintains that an arsonist started the fire and that police did not properly follow leads.

The cause of the fire was never determined and police never made an arrest.

"My position is that there was no emergency and the demolition charges were unlawful and unreasonable and should be reviewed by a court and disallowed as an unlawful taking of private property," the notice states.

Mr. Wisner is asking for $100,000 for the loss of the house and $900,000 for "harassment causing great mental stress and depression." He plans to retain an attorney, the notice states.

City Attorney Robert J. Slye said he did not want to comment about the notice when contacted Friday afternoon.

"We'll certainly wait to see what Mr. Wisner has to say and if he files a suit," he said.

Times staff writer David C. Shampine contributed to this report.

Source